Swedish Orphan Biovitrum AB Mutual Funds

Health Care & Life Sciences » Pharmaceuticals | Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB | Mutual Funds

Mutual Funds that own Swedish Orphan Biovitrum AB

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Fjarde AP Fonden

10,908,493

3.99%

10,908,493

0.86%

12/31/2016

EdgePoint Global Portfolio

8,051,044

2.95%

3,186,465

3.79%

12/31/2017

Swedbank Robur Ny Teknik

5,695,085

2.08%

7.09%

07/31/2018

Gladiator

4,495,000

1.65%

4,495,000

26.98%

12/31/2016

Lannebo Småbolag

3,998,300

1.46%

68,300

4.34%

12/31/2017

EdgePoint Global Growth & Income Portfolio

3,403,494

1.25%

1,569,754

2.69%

12/31/2017

Government Pension Fund - Global (The)

2,937,128

1.08%

-952,515

0.01%

12/31/2017

SEB Sverigefond

2,694,553

0.99%

-662,300

4.86%

12/31/2017

Vanguard Total International Stock Index Fund

2,282,112

0.84%

18,882

0.02%

07/31/2018

Lannebo Sverige 130/30

2,263,700

0.83%

143,700

8.1%

12/31/2017

About Swedish Orphan Biovitrum AB

View Profile

Address	Tomtebodavägen 23A Solna AB 112 76 Sweden
Employees	-
Website	http://www.sobi.com
Updated	07/08/2019
Swedish Orphan Biovitrum AB engages as a biopharmaceutical company. It provides therapies and services for patients with rare diseases. The firm's core products include Kineret within the inflammation therapeutic area; and Orfadin, Ammonaps, and Ammonul within the genetics and metabolic therapeutic area.